Selected data models

You must log in to select data models for download or further analysis.

224 Search results.
Relevance Rating New first Old first

VX-950HPC3006 NCT01571583 Follow-Up Assignment

- 11/17/21 - 1 form, 1 itemgroup, 3 items, 1 language
Itemgroup: Follow-Up Assignment
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 12-lead ECG (Local - Uns)

- 9/20/21 - 1 form, 1 itemgroup, 14 items, 1 language
Itemgroup: 12-lead Electrocardiogram
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 Questions

- 9/20/21 - 1 form, 1 itemgroup, 10 items, 1 language
Itemgroup: Questions
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 12-lead ECG - VX-950HPC3006 12-lead ECG

- 9/20/21 - 1 form, 1 itemgroup, 13 items, 1 language
Itemgroup: 12-lead Electrocardiogram
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 Concomitant Therapy

- 3/15/21 - 1 form, 1 itemgroup, 10 items, 1 language
Itemgroup: Concomitant Therapy
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

VX-950HPC3006 NCT01571583 Administration of TAC/CsA

- 3/15/21 - 1 form, 1 itemgroup, 9 items, 1 language
Itemgroup: Administration of TAC/CsA
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583

Effect of inhaled Fluticasone furoate and cellobiose octa-acetate on electrocardiographic parameters in healthy subjects, Study-ID: 101888 - Serology - screen for HIV antibody, hepatitis B and C

- 2/4/19 - 1 form, 2 itemgroups, 4 items, 1 language
Itemgroups: Administrative data, Serology - screen for HIV antibody, hepatitis B and C
Study ID: 101888 Clinical Study ID: FFR101888 Study Title: A randomised, placebo-controlled, four way crossover study to evaluate the effect of double-blind 4000 mcg of orally inhaled GW685698X and of 6.25 mg cellobiose octa-acetate on electrocardiographic parameters, with single-blind 400 mg of oral moxifloxacin as a positive control, in 40 healthy male and female subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Veramyst,Avamys,Allermist Study Indication: Rhinitis, Allergic, Perennial The study consists of a screening, 4 treatment periods (TP) and a follow-up visit. For each TP there is a Day-1 (D-1) and a Day1 (D1). This document contains the Serology - screen for HIV antibody, hepatitis B and C form. It has to be filled in for screening.

Eligibility NCT00803309 Hepatitis C, Chronic - Eligibility Hepatitis C NCT00803309

- 9/20/21 - 1 form, 2 itemgroups, 35 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
Chronic Hepatitis C: Optimization of Treatment for Patients infected With HCV-genotype 2 or 3: 12 vs. 24 Weeks of Treatment Extension for Patients Without Rapid Virological Response see http://clinicaltrials.gov/show/NCT00803309

Hepatitis C Eligibility NCT00299923 - Eligibility Hepatitis C, Chronic Relapse NCT00299923

- 9/20/21 - 1 form, 3 itemgroups, 173 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria, Medical Concepts
ODM derived from http://clinicaltrials.gov/show/NCT00299923 Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy

Eligibility Hepatitis C NCT02156570

- 9/27/21 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral); ODM derived from: https://clinicaltrials.gov/show/NCT02156570

Eligibility Hepatitis C Virus NCT02265237

- 9/27/21 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1); ODM derived from: https://clinicaltrials.gov/show/NCT02265237

Eligibility Hepatitis C, Chronic NCT01770483

- 9/27/21 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01770483

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial